- Home
- KZIA vs ERNA Comparison
KZIA vs ERNA Comparison
Compare KZIA & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- ERNA
- Stock Information
- Founded
- KZIA 1994
- ERNA 2018
- Country
- KZIA Australia
- ERNA United States
- Employees
- KZIA N/A
- ERNA N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- ERNA Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- ERNA Health Care
- Exchange
- KZIA Nasdaq
- ERNA Nasdaq
- Market Cap
- KZIA 11.7M
- ERNA 13.5M
- IPO Year
- KZIA 1999
- ERNA N/A
- Fundamental
- Price
- KZIA $8.68
- ERNA $1.69
- Analyst Decision
- KZIA Strong Buy
- ERNA
- Analyst Count
- KZIA 2
- ERNA 0
- Target Price
- KZIA $14.00
- ERNA N/A
- AVG Volume (30 Days)
- KZIA 675.5K
- ERNA 87.3K
- Earning Date
- KZIA 08-12-2025
- ERNA 08-15-2025
- Dividend Yield
- KZIA N/A
- ERNA N/A
- EPS Growth
- KZIA N/A
- ERNA N/A
- EPS
- KZIA N/A
- ERNA N/A
- Revenue
- KZIA $1,549,158.00
- ERNA $535,000.00
- Revenue This Year
- KZIA N/A
- ERNA N/A
- Revenue Next Year
- KZIA $49.25
- ERNA N/A
- P/E Ratio
- KZIA N/A
- ERNA N/A
- Revenue Growth
- KZIA 248983.08
- ERNA 365.22
- 52 Week Low
- KZIA $2.86
- ERNA $1.50
- 52 Week High
- KZIA $39.05
- ERNA $29.25
- Technical
- Relative Strength Index (RSI)
- KZIA 50.61
- ERNA 38.49
- Support Level
- KZIA $7.40
- ERNA $1.50
- Resistance Level
- KZIA $10.08
- ERNA $2.57
- Average True Range (ATR)
- KZIA 0.78
- ERNA 0.21
- MACD
- KZIA -0.29
- ERNA -0.01
- Stochastic Oscillator
- KZIA 42.38
- ERNA 17.76
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.